Bispecific T-cell Engagers (BiTEs)
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about what is the future for BiTEs versus CAR T therapies with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Maria Victoria Mateos (University of Salamanca, Spain).
This video is the first in a six-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society of Hematology (ASH) 60th annual convention which took place in San Diego, CA on December 2018.
- Bispecific T-cell Engagers (BiTEs)
- CAR T-cell Therapy
- Frontline Therapy
- Blood Monitoring
- MRD in Relapse
We thank supporters of this program:
Celgene Corporation, Karyopharm Therapeutics, and Takeda Oncology